COMPASS Pathways plc reported fourth quarter and full-year 2025 financial results, including a Q4 net loss of $93.9 million ($1.00 per share) and full-year net loss of $287.9 million ($3.08 per share), driven by non-cash warrant liability adjustments. The company announced plans for an FDA meeting to confirm NDA submission strategy for COMP360 in TRD by Q4 2026 and initiation of a Phase 2b/3 PTSD trial.
Key takeaways
Net loss for Q4 2025: $93.9 million or $1.00 per share basic and diluted, compared to $43.3 million or $0.63 per share in Q4 2024
Net loss for full-year 2025: $287.9 million or $3.08 per share basic and diluted, compared to $155.1 million or $2.30 per share in 2024
Cash and cash equivalents: $149.6 million as of December 31, 2025
Debt: $31.6 million as of December 31, 2025
Scheduled FDA meeting to confirm rolling NDA submission for COMP360 in TRD, with completion expected in Q4 2026
FDA accepted IND for Phase 2b/3 trial of COMP360 in PTSD
$150 million financing in February and $200 million warrants exercise extend cash runway into 2028